Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
- 1 August 2008
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (8) , 2013-2023
- https://doi.org/10.1038/jid.2008.44
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse modelMolecular Cancer Therapeutics, 2006
- A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase–Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen SpeciesCancer Research, 2006
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- Predicted mechanisms of resistance to mTOR inhibitorsBritish Journal of Cancer, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activityOncogene, 2005
- Evidence for Cyclin D3 as a Novel Target of Rapamycin in Human T LymphocytesJournal of Biological Chemistry, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- Human Melanoma Progression in Skin ReconstructsThe American Journal of Pathology, 2000